Lymphoblastic lymphoma

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 3, 2011, Pages 330-343

  Cortelazzo, Sergio ^a   Ponzoni, Maurilio ^b   Ferreri, Andrés J M ^b   Hoelzer, Dieter ^c  

^a Divisione de Nefrologia e Dialisi   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Onkologikum Frankfurt   (Germany)

Author keywords

Allogeneic transplant; Autologous stem cell transplant; CNS prophylaxis; Lymphoblastic lymphoma

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE DERIVATIVE; ASPARAGINASE; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; LACTATE DEHYDROGENASE; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; METHOTREXATE; NELARABINE; NITROSOUREA; PREDNISONE; RITUXIMAB; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; T6 ANTIGEN; TIOGUANINE; TRANSCRIPTION FACTOR PAX5; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORPHOLOGY; CANCER PREVENTION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER THERAPY; CERVICAL LYMPHADENOPATHY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG MEGADOSE; ENZYME BLOOD LEVEL; EVENT FREE SURVIVAL; FLOW CYTOMETRY; GENE REARRANGEMENT; GENETIC ASSOCIATION; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; INTRATHECAL DRUG ADMINISTRATION; LYMPHOBLASTOMA; MANTLE CELL LYMPHOMA; MEDIASTINUM DISEASE; MEDIASTINUM METASTASIS; MONOTHERAPY; MYELOID LEUKEMIA; OUTCOME ASSESSMENT; PATHOLOGY; PERICARDIAL EFFUSION; PLEURA EFFUSION; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; REVIEW; SEX RATIO; SKULL IRRADIATION; SUPERIOR CAVA VEIN SYNDROME; SURVIVAL RATE; T CELL LYMPHOMA; TRACHEA OBSTRUCTION; TREATMENT PLANNING; TUMOR BIOPSY; TUMOR CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; PROGNOSIS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 79960956065     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.12.003     Document Type: Review

References (112)

1. Borowitz M.J., Chan J.K. B lymphoblastic leukaemia/lymphoma, not otherwise specified. WHO classification of tumors of haematopoietic and lymphoid tissues 2008, 168-170. IARC. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S. Pileri, M. Stein, J. Thiele, J.W. Vardiman (Eds.).
2. Borowitz M.J., Chan J.K. B lymphoblastic leukaemia/lymphoma, with recurrent genetic abnormalitis. WHO classification of tumors of haematopoietic and lymphoid tissues 2008, 171-175. IARC. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S. Pileri, M. Stein, J. Thiele, J.W. Vardiman (Eds.).
3. Borowitz M.J., Chan J.K. T lymphoblastic leukaemia/lymphoma. WHO classification of tumors of haematopoietic and lymphoid tissues 2008, 176-178. IARC. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S. Pileri, M. Stein, J. Thiele, J.W. Vardiman (Eds.).
4. Hoelzer D., Gokbuget N. T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?. Clin Lymphoma Myeloma 2009, 9(Suppl. (3)):S214-S221.
5. Raetz E.A., Perkins S.L., Bhojwani D., et al. Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 2006, 47:130-140.
6. Uyttebroeck A., Suciu S., Laureys G., et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer 2008, 44:840-846.
7. Reiter A., Schrappe M., Ludwig W.D., et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000, 95:416-421.
8. Jabbour E., Koscielny S., Sebban C., et al. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 2006, 20:814-819.
9. A clinical evaluation of the international lymphoma classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood 1997, 89:3909-3918. LSG.
10. Groves F.D., Linet M.S., Travis L.B., Devesa S.S. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000, 92:1240-1251.
11. Soslow R.A., Baergen R.N., Warnke R.A. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 1999, 85:2648-2654.
12. Han X., Kilfoy B., Zheng T., et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008, 19:841-858.
13. Morton L.M., Wang S.S., Devesa S.S., et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
14. Goedert J.J., Cote T.R., Virgo P., et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998, 351:1833-1839.
15. Engels E.A., Cerhan J.R., Linet M.S., et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 2005, 162:1153-1161.
16. Ekstrom S.K., Vajdic C.M., Falster M., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008, 111:4029-4038.
17. Dharnidharka V.R., Tejani A.H., Ho P.L., Harmon W.E. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2002, 2:993-998.
18. Weisenburger D.D. Lymphoid malignancies in Nebraska: a hypothesis. Nebraska Med J 1985, 70:300-305.
19. Cantor K.P., Blair A., Everett G., et al. Pesticides and other agricultural risk factors for non-Hodgkin's lymphoma among men in Iowa and Minnesota. Cancer Res 1992, 52:2447-2455.
20. Yang Y.L., Lin S.R., Chen J.S., et al. Expression and prognostic significance of the apoptotic genes BCL2L13, Livin, and CASP8AP2 in childhood acute lymphoblastic leukemia. Leuk Res 2010, 34:18-23.
21. McCormack M.P., Young L.F., Vasudevan S., et al. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science 2010, 327:879-883.
22. Ferrando A.A. The role of NOTCH1 signaling in T-ALL. Hematology. Am Soc Hematol Educ Program 2009, 353-361.
23. Konn Z.J., Martineau M., Bown N., et al. Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia. Genes Chromosomes Cancer 2010, 49:253-259.
24. Pilozzi E., Pulford K., Jones M., et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol 1998, 186:140-143.
25. Natkunam Y., Zhao S., Mason D.Y., et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007, 109:1636-1642.
26. Cui W., Kong N.R., Ma Y., et al. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol 2006, 19:1585-1592.
27. Rytting M.E., Kantarjian H., Albitar M. Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity. Am J Clin Pathol 2009, 132:182-185.
28. Bernard A., Boumsell L., Reinherz E.L., et al. Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood 1981, 57:1105-1110.
29. Quintanilla-Martinez L., Zukerberg L.R., Harris N.L. Prethymic adult lymphoblastic lymphoma. A clinicopathologic and immunohistochemical analysis. Am J Surg Pathol 1992, 16:1075-1084.
30. Koita H., Suzumiya J., Ohshima K., et al. Lymphoblastic lymphoma expressing natural killer cell phenotype with involvement of the mediastinum and nasal cavity. Am J Surg Pathol 1997, 21:242-248.
31. Nakamura F., Tatsumi E., Kawano S., et al. Acute lymphoblastic leukemia/lymphoblastic lymphoma of natural killer (NK) lineage: quest for another NK-lineage neoplasm. Blood 1997, 89:4665-4666.
32. Millot F., Robert A., Bertrand Y., et al. Cutaneous involvement in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. The Children's Leukemia Cooperative Group of the European Organization of Research and Treatment of Cancer (EORTC). Pediatrics 1997, 100:60-64.
33. Maitra A., McKenna R.W., Weinberg A.G., Schneider N.R., Kroft S.H. Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. Am J Clin Pathol 2001, 115:868-875.
34. Rosenquist R., Lindh J., Roos G., Holmberg D. Immunoglobulin VH gene replacements in a T-cell lymphoblastic lymphoma. Mol Immunol 1997, 34:305-313.
35. Szczepanski T., Pongers-Willemse M.J., Langerak A.W., et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 1999, 93:4079-4085.
36. Thomas D.A., Kantarjian H.M. Lymphoblastic lymphoma. Hematol Oncol Clin North Am 2001, 15:51-95, vi.
37. Lones M.A., Heerema N.A., Le Beau M.M., et al. Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer Genet Cytogenet 2007, 172:1-11.
38. Kaneko Y., Shikano T., Maseki N., et al. Clinical characteristics of infant acute leukemia with or without 11q23 translocations. Leukemia 1988, 2:672-676.
39. Abruzzo L.V., Jaffe E.S., Cotelingam J.D., et al. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol 1992, 16:236-245.
40. Inhorn R.C., Aster J.C., Roach S.A., et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 1995, 85:1881-1887.
41. Thandla S., Alashari M., Green D.M., Aplan P.D. Therapy-related T cell lymphoblastic lymphoma with t(11;19)(q23;p13) and MLL gene rearrangement. Leukemia 1999, 13:2116-2118.
42. Metzgeroth G., Walz C., Score J., et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007, 21:1183-1188.
43. Salloum E., Henry-Amar M., Caillou B., et al. Lymphoblastic lymphoma in adults: a clinicopathological study of 34 cases treated at the Institut Gustave-Roussy. Eur J Cancer Clin Oncol 1988, 24:1609-1616.
44. Shafer D., Wu H., Al-Saleem T., et al. Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature. Arch Dermatol 2008, 144:1155-1162.
45. Soslow R.A., Bhargava V., Warnke R.A. MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities. Hum Pathol 1997, 28:1158-1165.
46. Hoelzer D., Gokbuget N., Digel W., et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002, 99:4379-4385.
47. Engelhard M., Brittinger G., Gerharts H.H., et al. LBL: results of a prospective treatment trial (BMFT study). Br J Heatol 1996, 93:1391a.
48. Streuli R.A., Kaneko Y., Variakojis D., et al. Lymphoblastic lymphoma in adults. Cancer 1981, 47:2510-2516.
49. Copelan E.A., McGuire E.A. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995, 85:1151-1168.
50. Tsukamoto N., Kojima M., Hasegawa M., et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67) gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007, 110:652-659.
51. Murphy S.B., Fairclough D.L., Hutchison R.E., Berard C.W. Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989, 7:186-193.
52. Coleman C.N., Picozzi V.J.J., Cox R.S., et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986, 4:1628-1637.
53. Bassan R., Spinelli O., Oldani E., et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009, 113:4153-4162.
54. Coustan-Smith E., Abromowitz M., Sandlund J.T., Campana D. A novel approach for minimal residual disease detection in childhood T-cell lymphoblastic lymphoma (T-LL): a children's oncology group report. Blood (ASH Annual Meeting Abstracts) 2007, 110:3564.
55. Neth O., Seidemann K., Jansen P., et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol 2000, 35:20-27.
56. Thomas D.A., O'Brien S., Cortes J., et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004, 104:1624-1630.
57. Cortelazzo S., Intermesoli T., Oldani E., et al. A phase II study on intensive ALL-type chemotherapy with minimal residual disease (MRD) oriented postremission strategy in adult patients wiyth LBL (protocol NILG-ALL 09/00). Haematologica 2008, s1:305.
58. Pillon M., Piglione M., Garaventa A., et al. Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer 2009, 53:953-959.
59. Anderson J.R., Jenkin R.D., Wilson J.F., et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 1993, 11:1024-1032.
60. Link M.P., Donaldson S.S., Berard C.W., Shuster J.J., Murphy S.B. Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 1990, 322:1169-1174.
61. Lones M.A., Perkins S.L., Sposto R., et al. Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol 2002, 20:2293-2301.
62. Hvizdala E.V., Berard C., Callihan T., et al. Lymphoblastic lymphoma in children-a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study. J Clin Oncol 1988, 6:26-33.
63. Patte C., Kalifa C., Flamant F., et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 1992, 20:105-113.
64. Hoelzer D., Gokbuget N. Treatment of lymphoblastic lymphoma in adults. Best Pract Res Clin Haematol 2002, 15:713-728.
65. INHLPFP The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329:987-994.
66. Sweetenham J.W., Santini G., Qian W., et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001, 19:2927-2936.
67. Anderson J.R., Wilson J.F., Jenkin D.T., et al. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983, 308:559-565.
68. Dahl G.V., Rivera G., Pui C.H., et al. A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early and intermittent use of teniposide plus cytarabine. Blood 1985, 66:1110-1114.
69. Weinstein H.J., Cassady J.R., Levey R. Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1983, 1:537-541.
70. Wollner N., Burchenal J.H., Lieberman P.H., et al. Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy. Cancer 1976, 37:123-134.
71. Bouabdallah R., Xerri L., Bardou V.J., et al. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol 1998, 9:619-625.
72. Jost L.M., Jacky E., Dommann-Scherrer C., et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients. Ann Oncol 1995, 6:445-451.
73. Le G.S., Lepretre S., Briere J., et al. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia 2003, 17:2220-2224.
74. Mora J., Filippa D.A., Qin J., Wollner N. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer 2003, 98:1283-1291.
75. Slater D.E., Mertelsmann R., Koziner B., et al. Lymphoblastic lymphoma in adults. J Clin Oncol 1986, 4:57-67.
76. Morel P., Lepage E., Brice P., et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 1992, 10:1078-1085.
77. Zinzani P.L., Bendandi M., Visani G., et al. Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma 1996, 23:577-582.
78. Willemze R., Zijlmans J.M., den Ottolander G.J., et al. High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma. Ann Hematol 1995, 70:71-74.
79. Amylon M.D., Shuster J., Pullen J., et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999, 13:335-342.
80. Tibes R., Keating M.J., Ferrajoli A., et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 2006, 106:2645-2651.
81. Golay J., Cortiana C., Manganini M., et al. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica 2006, 91:322-330.
82. Cooper T.M. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manage 2007, 3:1135-1141.
83. DeAngelo D.J., Yu D., Johnson J.L., et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007, 109:5136-5142.
84. Rytting M., Thomas D., Franklin A., et al. Young adults with acute lymphoblastic leukemia (ALL) treated with adapted augmented Berlin-Frankfurt-Munster (ABFM) therapy. Blood (ASH Annual Meeting Abstracts) 2008, 112:3957.
85. Hoelzer D., Huettmann A.M., Kaul F.K., et al. Immunochemotherapy with rituzimab in adult CD20+ B-precursor all improves molecular CR rate and outcome in standard risk (SR) as well as in high rish (HR) patients with SCT. Haematologica 2009, 94(Suppl. (2)):195.
86. Kebriaei P., Saliba R.M., Ma C., et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 2006, 38:203-209.
87. Jaime-Perez J.C., Rodriguez-Romo L.N., Gonzalez-Llano O., Chapa-Rodriguez A., Gomez-Almaguer D. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol 2009, 144:794-795.
88. Sweetenham J.W., Mead G.M., Whitehouse J.M. Adult lymphoblastic lymphoma: high incidence of central nervous system relapse in patients treated with the Stanford University protocol. Ann Oncol 1992, 3:839-841.
89. Langer T., Martus P., Ottensmeier H., et al. CNS late-effects after ALL therapy in childhood, Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med Pediatr Oncol 2002, 38:320-328.
90. Glover D.A., Byrne J., Mills J.L., et al. Impact of CNS treatment on mood in adult survivors of childhood leukemia: a report from the Children's Cancer Group. J Clin Oncol 2003, 21:4395-4401.
91. Bongers M.E., Francken A.B., Rouwe C., Kamps W.A., Postma A. Reduction of adult height in childhood acute lymphoblastic leukemia survivors after prophylactic cranial irradiation. Pediatr Blood Cancer 2005, 45:139-143.
92. Burkhardt B., Woessmann W., Zimmermann M., et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006, 24:491-499.
93. Hancock S.L., Donaldson S.S., Hoppe R.T. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993, 11:1208-1215.
94. Bhatia S., Robison L.L., Oberlin O., et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996, 334:745-751.
95. Ingram L., Mott M.G., Mann J.R., et al. Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimens. Br J Cancer 1987, 55:463-466.
96. Baro J., Richard C., Sierra J., et al. Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy. Bone Marrow Transplant 1992, 10:33-38.
97. Sweetenham J.W., Liberti G., Pearce R., et al. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. J Clin Oncol 1994, 12:1358-1365.
98. Aljurf M., Zaidi S.Z. Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies. Biol Blood Marrow Transplant 2005, 11:739-754.
99. Verdonck L.F., Dekker A.W., de Gast G.C., Lokhorst H.M., Nieuwenhuis H.K. Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission. J Clin Oncol 1992, 10:644-646.
100. Santini G., Congiu A.M., Coser P., et al. Autologous bone marrow transplantation for adult advanced stage lymphoblastic lymphoma in first CR. a study of the NHLCSG. Leukemia 1991, 5(Suppl (1)):42-45.
101. Conde E., Zuazu J., Lopez-Guillermo A., et al. Autologous stem cell transplantation (ASCT) for LBL (LBL). Blood 1999, 94(Suppl (1)):477a.
102. De Witte T., Awwad B., Boezeman J., et al. Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant 1994, 14:767-774.
103. van Besien K.W., Mehra R.C., Giralt S.A., et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 1996, 100:299-307.
104. Levine J.E., Harris R.E., Loberiza F.R., et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003, 101:2476-2482.
105. Philip T., Hartmann O., Pinkerton R., et al. Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Societe Francaise d'Oncologie Pediatrique. Blood 1993, 81:2003-2006.
106. Mai W., Meng H., Jin J., Wang L. Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol 2006, 77:445-447.
107. Crazzolara R., Bradstock K.F., Bendall L.J. RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 2009, 5:727-728.
108. Chiarini F., Fala F., Tazzari P.L., et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009, 69:3520-3528.
109. Hussain A.R., Al-Rasheed M., Manogaran P.S., et al. Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006, 11:245-254.
110. Cullion K., Draheim K.M., Hermance N., et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009, 113:6172-6181.
111. Medyouf H., Alcalde H., Berthier C., et al. Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nat Med 2007, 13:736-741.
112. Kreitman R.J. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des 2009, 15:2652-2664.